6-Month, Multicenter, Randomized, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Antihyperglycemic Drugs
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EDITION AP
- Sponsors Sanofi
- 21 Sep 2017 Planned End Date changed from 1 Sep 2018 to 13 Aug 2018.
- 21 Sep 2017 Planned primary completion date changed from 1 Sep 2018 to 13 Aug 2018.
- 10 Jun 2017 Biomarkers information updated